193 related articles for article (PubMed ID: 26148625)
21. Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma.
Alsahlawi AK; Michaud-Couture C; Lachance A; Bergeron-Gravel S; Létourneau M; Bourget C; Gould PV; Giannakouros P; Nakada EM; Faury D; Crevier L; Bouffet É; Jabado N; Larouche V; Renzi S
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e87-e90. PubMed ID: 38032194
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.
Liu AK; Macy ME; Foreman NK
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1148-54. PubMed ID: 19857784
[TBL] [Abstract][Full Text] [Related]
23. Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients.
Wang Y; Pan L; Sheng X; Mao Y; Yao Y; Wang E; Zhang N; Dai J
Eur J Med Res; 2012 Aug; 17(1):25. PubMed ID: 22913802
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.
Furuse M; Nonoguchi N; Kawabata S; Miyata T; Toho T; Kuroiwa T; Miyatake S
Radiat Oncol; 2015 Jul; 10():156. PubMed ID: 26223253
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in the treatment of radiation injury for children with central nervous system tumors.
Dahl NA; Liu AK; Foreman NK; Widener M; Fenton LZ; Macy ME
Childs Nerv Syst; 2019 Nov; 35(11):2043-2046. PubMed ID: 31367784
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
Khan M; Zhao Z; Arooj S; Liao G
BMC Cancer; 2021 Feb; 21(1):167. PubMed ID: 33593308
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience.
Sadraei NH; Dahiya S; Chao ST; Murphy ES; Osei-Boateng K; Xie H; Suh JH; Peereboom DM; Stevens GH; Ahluwalia MS
Am J Clin Oncol; 2015 Jun; 38(3):304-10. PubMed ID: 23799286
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial.
Xu Y; Rong X; Hu W; Huang X; Li Y; Zheng D; Cai Z; Zuo Z; Tang Y
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1087-1095. PubMed ID: 29885994
[TBL] [Abstract][Full Text] [Related]
29. Radiation retinopathy after external beam irradiation for nasopharyngeal carcinoma: A case report and review of the literature.
Bawankar P; Barman M; Bhattacharjee H; Soibam R; Paulbuddhe V
Pract Radiat Oncol; 2018; 8(6):366-368. PubMed ID: 29861351
[No Abstract] [Full Text] [Related]
30. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.
Torcuator R; Zuniga R; Mohan YS; Rock J; Doyle T; Anderson J; Gutierrez J; Ryu S; Jain R; Rosenblum M; Mikkelsen T
J Neurooncol; 2009 Aug; 94(1):63-8. PubMed ID: 19189055
[TBL] [Abstract][Full Text] [Related]
31. Severe Radiation Necrosis Successfully Treated With Bevacizumab in an Infant with Low-Grade Glioma and Tumor-Associated Intractable Trigeminal Neuralgia.
Pillay Smiley N; Alden T; Hartsell W; Fangusaro J
Pediatr Blood Cancer; 2016 Sep; 63(9):1671-3. PubMed ID: 27187113
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET.
Furuse M; Nonoguchi N; Kawabata S; Yoritsune E; Takahashi M; Inomata T; Kuroiwa T; Miyatake S
Jpn J Clin Oncol; 2013 Mar; 43(3):337-41. PubMed ID: 23303838
[TBL] [Abstract][Full Text] [Related]
33. Exacerbation of cerebral radiation necrosis by bevacizumab.
Jeyaretna DS; Curry WT; Batchelor TT; Stemmer-Rachamimov A; Plotkin SR
J Clin Oncol; 2011 Mar; 29(7):e159-62. PubMed ID: 21149667
[No Abstract] [Full Text] [Related]
34. Intravitreal bevacizumab for radiation-induced cystoid macular oedema in patients with nasopharyngeal carcinoma: a clinical series.
Subrayan V; Khaw KW; Peyman M; Koay AC; Tajunisah I
Ophthalmologica; 2013; 229(4):208-11. PubMed ID: 23548379
[TBL] [Abstract][Full Text] [Related]
35. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
[TBL] [Abstract][Full Text] [Related]
36. Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial.
Tang Y; Rong X; Hu W; Li G; Yang X; Yang J; Xu P; Luo J
J Neurooncol; 2014 Nov; 120(2):441-7. PubMed ID: 25142813
[TBL] [Abstract][Full Text] [Related]
37. [Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].
Chen Y; Wang X; Sun B; Meng M; Wang E; Yuan Z; Zhuang H;
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):291-294. PubMed ID: 35570144
[TBL] [Abstract][Full Text] [Related]
38. Radiation necrosis of the pons after radiotherapy for nasopharyngeal carcinoma: diagnosis and treatment.
DeSalvo MN
J Radiol Case Rep; 2012 Jul; 6(7):9-16. PubMed ID: 23365707
[TBL] [Abstract][Full Text] [Related]
39. Place of bevacizumab in radiation-induced edema and necrosis.
Benderli Cihan Y
J BUON; 2016; 21(4):1026-1027. PubMed ID: 27685931
[No Abstract] [Full Text] [Related]
40. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
